RE: Technical considerations in obtaining platelet-rich fibrin for clinical and periodontal research

We are writing to you regarding the recent publication by Bains et al.,1 which appeared in your esteemed journal. As a researcher whose studies were cited in this narrative review, we would like to commend the authors for their efforts to contribute to the scientific discourse. Nevertheless, there are a few inaccuracies that I believe should be addressed to enhance the article's precision and reliability.

The first point pertains to the data presented in Table 1. There appears to be a misinterpretation regarding the nomenclature of heated platelet-rich fibrin (PRF). Specifically, the term “Alb-PRF” is attributed to Kawase et al.2 However, their study did not define the PRF membrane post-heating with this nomenclature. It was actually Mourão et al. who, in a 2018 publication, first described the blood by-product, combining the albumin gel with the liquid platelet-rich fibrin, which was obtained through the Medifuge protocol (Silfradent S.r.l., Santa Sofia, Italy) and at that time was called “Alb-CGF”.3 The term “Alb-PRF” was subsequently introduced in a study by Fujioka-Kobayashi et al.,4 and it builds upon the principles set forth by Mourão et al.